|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1201 Maryland Avenue SW |
Address2 | Suite 900 |
| City | Washington |
State | DC |
Zip Code | 20024 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 6245-12
|
||||||||
|
6. House ID# 325050000
|
||||||||
| TYPE OF REPORT | 8. Year | 2021 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Jeanne Haggerty |
Date | 7/20/2021 10:14:07 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code AGR
16. Specific lobbying issues
Climate Change
---H.R.7393/S.3894: The Growing Climate Solutions Act of 2020
---FY 2022 Appropriations
---Climate Risk Disclosures
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Fighting Climate Change through Biotechnology Innovation
---RFI from House Select Committee on the Climate Crisis
Foreign Agricultural Biotechnology Laws and Regulations
---China Biotechnology Regulations
---EU Ag-Biotech Policies and Regulations
---Mexico Draft Decree Banning Genetically Modified Corn
---Mexico Import Approval Delays of Ag Biotech
Funding for the USDA
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House)
Genetically Engineered (GE) Animals
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House)
------GE Salmon
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Efficient Science-Based Review of Biotech Products
---FDA Approvals, Guidance, & Regulations
---Labeling
---USDA proposed Regulation of the Movement of Animals Modified or Developed by Genetic Engineering
Genetically Engineered (GE) Plants
---Climate Issues & impact on the agriculture, food, and forestry sectors
---EPA Regulatory Approach to Gene Editing
Review and Labeling of Food Derived from Biotechnology
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House)
------GE Salmon
---Implementation of Disclosure Law
USDA/APHIS Agricultural Biotechnology Regulations
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House)
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Regulatory Treatment of Gene Edited Products
---USDA proposed Regulation of the Movement of Animals Modified or Developed by Genetic Engineering
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), U.S. Trade Representative (USTR), Food & Drug Administration (FDA), White House Office, Environmental Protection Agency (EPA), Natl Security Council (NSC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Erick |
Lutt |
|
|
|
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Michael |
Mattoon |
|
|
|
Matthew |
O'Mara |
|
|
|
Joseph |
Damond |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ANI
16. Specific lobbying issues
Genetically Engineered (GE) Animals
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House)
------GE Salmon
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Efficient Science-Based Review of Biotech Products
---FDA Approvals, Guidance, & Regulations
---Labeling
---USDA proposed Regulation of the Movement of Animals Modified or Developed by Genetic Engineering
Review and Labeling of Food Derived from Biotechnology
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House)
------GE Salmon
---Implementation of Disclosure Law
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jeanne |
Haggerty |
|
|
|
Michael |
Mattoon |
|
|
|
Hayley |
Alexander |
|
|
|
Erick |
Lutt |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Coronavirus (COVID-19) Pandemic
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1319: American Rescue Plan Act of 2021
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
Funding for Antimicrobial Resistance (AMR) Programs
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1319: American Rescue Plan Act of 2021
---H.R. 8920/S.4760: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2021
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1319: American Rescue Plan Act of 2021
---Funding for Strategic National Stockpile
---Health Defense Operations Funding Designation
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
Funding for Biofuels, Biomass Crop Assistance, and Biorefineries
---FY 2022 Appropriations
---S.1260: United States Innovation and Competition Act of 2021
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House)
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Incentives for Sustainable Aviation Fuels
Funding for FDA
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.3743: Supporting the Foundation for the National Institutes of Health and the Reagan-Udall Foundation for the Food and Drug Administration Act
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of the Prescription Drug User Fee Act (PDUFA) VI
---Prescription Drug User Fee Act (PDUFA) VII Priorities
Funding for Health Resources and Services Administration (HRSA)
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1319: American Rescue Plan Act of 2021
Funding for National Institutes of Health
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1319: American Rescue Plan Act of 2021
---H.R.3743: Supporting the Foundation for the National Institutes of Health and the Reagan-Udall Foundation for the Food and Drug Administration Act
---Advanced Research Projects Agency for Health (ARPA-H)
Funding for Renewable Chemicals/Bio-based Products
---FY 2022 Appropriations
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House)
Funding for the Centers for Disease Control and Prevention Vaccine Programs
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1319: American Rescue Plan Act of 2021
---Funding for 2020-2021 Influenza Season Preparedness and Response
---Funding for Routine Immunization Infrastructure during Pandemic
Funding for the USDA
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House)
---Biotechnology and Agriculture Trade Program
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Agriculture - Dept of (USDA), Office of Science & Technology Policy (OSTP)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Erick |
Lutt |
|
|
|
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Michael |
Mattoon |
|
|
|
Cartier |
Esham |
|
|
|
Camelia |
Thompson |
|
|
|
Joel |
Straus |
|
|
|
Phyllis |
Arthur |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CHM
16. Specific lobbying issues
Funding for Renewable Chemicals/Bio-based Products
---FY 2022 Appropriations
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House)
Renewable Chemicals/Bio-based Products (Non-Funding)
---H.R.1512: The Climate Leadership and Environmental Action for Our Nations (CLEAN) Future Act of 2021
---H.R.2532: Renewable Chemicals Act of 2021
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Implementation of the Agriculture Improvement Act of 2018
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Erick |
Lutt |
|
|
|
Jeanne |
Haggerty |
|
|
|
Michael |
Mattoon |
|
|
|
Hayley |
Alexander |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Antitrust Legislation
---S.225: Competition and Antitrust Law Enforcement Reform Act of 2021
Bayh-Dole Act/Tech Transfer
---FY 2022 Appropriations
---Bayh-Dole Act
---March-In Rights
---NIST Proposed Rulemaking on Bayh-Dole
Compulsory Licensing
Coronavirus (COVID-19) Pandemic
---Restrictions on Intellectual Property Rights
Diversity in Patenting
---35 USC Section 101 on Patent Eligibility
---S.632: Inventor Diversity for Economic Advancement (IDEA) Act of 2021
Drug Patenting
---H.R.19/S.2164: Lower Costs, More Cures Act of 2021
---H.R.153: Protecting Consumer Access to Generic Drugs Act of 2021
---H.R.2873: Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
---H.R.2884: Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2021
---S.1435: Affordable Prescriptions for Patients Act of 2021
---Lower Health Care Costs for Patients Act (Discussion Draft)
---Medicare Negotiation and Competitive Licensing Act (Discussion Draft)
---Restrictions on Intellectual Property Rights
Intellectual Property Enforcement
---China
---General Patent Reform
---TRIPS Waiver
Inter Partes Review
---Support Technology and Research for Our Nations Growth and Economic Resilience (STRONGER) Patents Act (Discussion Draft)
Patent Reform
---H.R.7259/S.2814: Patents for Humanity Program Improvement Act of 2020
---S.1260: United States Innovation and Competition Act of 2021
------Ownership and Assignments of Patents
---Patent Litigation Reforms
Patenting of Biological Inventions
---35 USC Section 101 on Patent Eligibility
---DNA Patenting and Licensing
---Section 101 Modernization
United States-Mexico-Canada Agreement (USMCA)
---Implementation of USMCA
------IP Provisions
US-China Trade Agreement
---IP Provisions
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), Patent & Trademark Office (PTO), Commerce - Dept of (DOC), White House Office, Federal Trade Commission (FTC), Natl Security Council (NSC)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Lachmann |
|
|
|
Hans |
Sauer |
|
|
|
Jeanne |
Haggerty |
|
|
|
Michael |
Mattoon |
|
|
|
Hayley |
Alexander |
|
|
|
Joseph |
Damond |
|
|
|
Melissa |
Brand |
|
|
|
Aiken |
Hackett |
|
|
|
Kate |
Callanan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENG
16. Specific lobbying issues
Biofuels (Non-Funding)
---H.R.1113: Renewable Fuel Standard Integrity Act of 2021
---H.R.1512: The Climate Leadership and Environmental Action for Our Nations (CLEAN) Future Act of 2021
---H.R.3440/S.2263: Sustainable Skies Act of 2021
---S.193: Adopt Greenhouse gases, Regulated Emissions, and Energy use in Transportation model (GREET) Act
---S.218: A bill to approve certain advanced biofuel registrations, to require the consideration of certain advanced biofuel pathways, and to reduce greenhouse gas emissions, and for other purposes.
---S.2118: Clean Energy for America Act of 2021
---A Clean Fuel Standard or Low Carbon Fuel Standard
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Incentives for Sustainable Aviation Fuels
---Small Refinery Waivers
---Sustainable Aviation Fuels Tax Credit
Biomass Programs (Non-Funding)
---Climate Issues & impact on the agriculture, food, and forestry sectors
Biorefineries (Non-Funding)
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies for FY 2022
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Implementation of the Agriculture Improvement Act of 2018
Climate Change
---FY 2022 Appropriations
---S.1251/H.R.2820: Growing Climate Solutions Act of 2021
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Fighting Climate Change through Biotechnology Innovation
Funding for Biofuels, Biomass Crop Assistance, and Biorefineries
---FY 2022 Appropriations
---S.1260: United States Innovation and Competition Act of 2021
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House)
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Incentives for Sustainable Aviation Fuels
Renewable Fuel Standard (RFS)
---H.R.1113: Renewable Fuel Standard Integrity Act of 2021
---H.R.1512: The Climate Leadership and Environmental Action for Our Nations (CLEAN) Future Act of 2021
---S.193: Adopt Greenhouse gases, Regulated Emissions, and Energy use in Transportation model (GREET) Act
---S.218: A bill to approve certain advanced biofuel registrations, to require the consideration of certain advanced biofuel pathways, and to reduce greenhouse gas emissions, and for other purposes.
---A Clean Fuel Standard or Low Carbon Fuel Standard
---Cellulosic Registration Applications for Corn Kernel Fiber
---Climate Issues & impact on the agriculture, food, and forestry sectors
---RFS Reform
---Small Refinery Waivers
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Environmental Protection Agency (EPA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Erick |
Lutt |
|
|
|
Jeanne |
Haggerty |
|
|
|
Michael |
Mattoon |
|
|
|
Hayley |
Alexander |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FOO
16. Specific lobbying issues
Genetically Engineered (GE) Animals
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House)
------GE Salmon
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Efficient Science-Based Review of Biotech Products
---FDA Approvals, Guidance, & Regulations
---Labeling
---USDA proposed Regulation of the Movement of Animals Modified or Developed by Genetic Engineering
Review and Labeling of Food Derived from Biotechnology
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House)
------GE Salmon
---Implementation of Disclosure Law
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Food & Drug Administration (FDA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jeanne |
Haggerty |
|
|
|
Michael |
Mattoon |
|
|
|
Hayley |
Alexander |
|
|
|
Erick |
Lutt |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FUE
16. Specific lobbying issues
Biofuels (Non-Funding)
---H.R.1113: Renewable Fuel Standard Integrity Act of 2021
---H.R.1512: The Climate Leadership and Environmental Action for Our Nations (CLEAN) Future Act of 2021
---H.R.3440/S.2263: Sustainable Skies Act of 2021
---S.193: Adopt Greenhouse gases, Regulated Emissions, and Energy use in Transportation model (GREET) Act
---S.218: A bill to approve certain advanced biofuel registrations, to require the consideration of certain advanced biofuel pathways, and to reduce greenhouse gas emissions, and for other purposes.
---S.2118: Clean Energy for America Act of 2021
---A Clean Fuel Standard or Low Carbon Fuel Standard
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Incentives for Sustainable Aviation Fuels
---Small Refinery Waivers
---Sustainable Aviation Fuels Tax Credit
Biomass Programs (Non-Funding)
---Climate Issues & impact on the agriculture, food, and forestry sectors
Biorefineries (Non-Funding)
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies for FY 2022
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Implementation of the Agriculture Improvement Act of 2018
Climate Change
---FY 2022 Appropriations
---S.1251/H.R.2820: Growing Climate Solutions Act of 2021
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Fighting Climate Change through Biotechnology Innovation
Funding for Biofuels, Biomass Crop Assistance, and Biorefineries
---FY 2022 Appropriations
---S.1260: United States Innovation and Competition Act of 2021
---Agriculture, Rural Development, Food and Drug Administration, and Related Agencies appropriations bill for FY 2022 (Discussion Draft House)
---Climate Issues & impact on the agriculture, food, and forestry sectors
---Incentives for Sustainable Aviation Fuels
Renewable Fuel Standard (RFS)
---H.R.1113: Renewable Fuel Standard Integrity Act of 2021
---H.R.1512: The Climate Leadership and Environmental Action for Our Nations (CLEAN) Future Act of 2021
---S.193: Adopt Greenhouse gases, Regulated Emissions, and Energy use in Transportation model (GREET) Act
---S.218: A bill to approve certain advanced biofuel registrations, to require the consideration of certain advanced biofuel pathways, and to reduce greenhouse gas emissions, and for other purposes.
---A Clean Fuel Standard or Low Carbon Fuel Standard
---Cellulosic Registration Applications for Corn Kernel Fiber
---Climate Issues & impact on the agriculture, food, and forestry sectors
---RFS Reform
---Small Refinery Waivers
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Agriculture - Dept of (USDA), Environmental Protection Agency (EPA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Erick |
Lutt |
|
|
|
Jeanne |
Haggerty |
|
|
|
Michael |
Mattoon |
|
|
|
Hayley |
Alexander |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
21st Century Cures Act 2.0
---House Discussion Draft
---RFI from House Energy and Commerce Committee
340B Drug Discount Program
---H.R.3203: A bill to enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes.
---Program Implementation & Oversight
Biodefense Research, Development and Procurement Issues (Non-Funding)
---Executive Order on Modernizing Influenza Vaccines
---White House National Biodefense Strategy
Biosimilars
---BSUFA Negotiations
Coronavirus (COVID-19) Pandemic
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.869/S.289: Research Investment to Spark the Economy (RISE) Act of 2021
---H.R.1319: American Rescue Plan Act of 2021
---COVID-19 Lessons Learned
---COVID-19 Pricing-Related Provisions
---COVID-19 Vaccine Distribution
---Defense Production Act (DPA)
---Drug Supply Chain Management
---Healthcare Disparities
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Medicare Reimbursement Policies
---Monoclonal Antibody Coverage and Utilization
---Patient Cost-Sharing and Smoothing
---PREP Act COVID-19 Declaration Coverage for Private Sector Procurement
---R&D Funding for Medical Countermeasures
---Senate HELP Pandemic Preparedness White Paper
---Supply Chain Issues
---TRIPS IP Waiver
Diversity & Inclusion
---Clinical Trial Diversity
Drug Evaluation and Review
---COVID-19 Lessons Learned
---Compassionate Use/Expanded Access
---Expedited Pathways
---FDA Hiring Flexibility
---FDA Management and Financial Accountability
---Patient-Focused Drug Development
---Prescription Drug User Fee Act (PDUFA) VII Priorities
---Priority Review Voucher Programs
---Promising Pathway Act (Discussion Draft)
---Regulatory Reform & Modernization
---Use of Real-World Evidence
Drug Manufacturing, Quality & Distribution
---A bill to amend the Internal Revenue Code of 1986 to provide for credits against tax for domestic medical and drug manufacturing and advanced medical manufacturing equipment. (Discussion Draft)
---Executive Order on Buy American
---Supply Chain Integrity and Traceability
Drug Patenting
---H.R.19/S.2164: Lower Costs, More Cures Act of 2021
---H.R.153: Protecting Consumer Access to Generic Drugs Act of 2021
---H.R.2873: Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
---H.R.2884: Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2021
---S.1435: Affordable Prescriptions for Patients Act of 2021
---Lower Health Care Costs for Patients Act (Discussion Draft)
---Medicare Negotiation and Competitive Licensing Act (Discussion Draft)
---Restrictions on Intellectual Property Rights
Drug Pricing
---FY 2022 Appropriations
---H.R.3: Elijah E. Cummings Lower Drug Costs Now Act
---H.R.19/S.2164: Lower Costs, More Cures Act of 2021
---CMMI Authority
---COVID-19 Pricing-Related Provisions
---Drug Pricing Provisions
---Prescription Drug Pricing Reduction Act (Discussion Draft)
---Reference Pricing in Drug Reimbursement
---Senate Finance Committee Drug Pricing Principles
---Strengthening Innovation in Medicare and Medicaid Act (Discussion Draft)
Funding for Antimicrobial Resistance Programs
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1319: American Rescue Plan Act of 2021
---H.R. 8920/S.4760: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2021
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1319: American Rescue Plan Act of 2021
---Funding for Strategic National Stockpile
---Health Defense Operations Funding Designation
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
Funding for FDA
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.3743: Supporting the Foundation for the National Institutes of Health and the Reagan-Udall Foundation for the Food and Drug Administration Act
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
---Implementation of the Prescription Drug User Fee Act (PDUFA) VI
---Prescription Drug User Fee Act (PDUFA) VII Priorities
Funding for Health Resources and Services Administration (HRSA)
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1319: American Rescue Plan Act of 2021
Funding for National Institutes of Health
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1319: American Rescue Plan Act of 2021
---H.R.3743: Supporting the Foundation for the National Institutes of Health and the Reagan-Udall Foundation for the Food and Drug Administration Act
---Advanced Research Projects Agency for Health (ARPA-H)
Funding for the Centers for Disease Control and Prevention Vaccine Programs
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1319: American Rescue Plan Act of 2021
---Funding for 2020-2021 Influenza Season Preparedness and Response
---Funding for Routine Immunization Infrastructure during Pandemic
Medicaid
---H.R.3: Elijah E. Cummings Lower Drug Costs Now Act
---H.R.2170/S.581: Helping Adults Protect Immunity (HAPI) Act of 2021
---H.R.2347: Strengthening the Vaccines for Children Program Act of 2021
---Pricing and Rebates
---Senate Finance Committee Drug Pricing Principles
---Value-Based Purchasing (VBP) Rule
Reimbursement and Coverage of Innovative Products
---H.R.3: Elijah E. Cummings Lower Drug Costs Now Act
---H.R.19/S.2164: Lower Costs, More Cures Act of 2021
---CMMI Authority
---Drug Pricing Provisions
---Medicare Part B Physician-Administered Products
---New Opportunities for Value that Extend Lives (NOVEL) Act (Discussion Draft)
---Patient Cost-Sharing and Smoothing
---Protected Classes
---Reference Pricing in Drug Reimbursement
---Senate Finance Committee Drug Pricing Principles
---Strengthening Innovation in Medicare and Medicaid Act (Discussion Draft)
---Value-Based Purchasing (VBP) Rule
---Value-based Contracting and Communications
Vaccines and Infectious Diseases
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.550: Immunization Infrastructure Modernization Act
---H.R.951: Maternal Vaccinations Act
---H.R.979: Vaccine Fairness Act
---H.R.1319: American Rescue Plan Act of 2021
---H.R.1452: A bill to direct the Secretary of Health and Human Services to publish the formula the Secretary uses to determine the allocation of COVID-19 vaccines, and for other purposes.
---H.R.1550: Promoting Resources to Expand Vaccination, Education, and New Treatments for (PREVENT) HPV Cancers Act of 2021
---H.R.1978: Protecting Seniors through Immunizations Act
---H.R.2170/S.581: Helping Adults Protect Immunity (HAPI) Act of 2021
---H.R.2347: Strengthening the Vaccines for Children Program Act of 2021
---H.R.3013: COVID Vaccine Transportation Access Act
---H.R.3655: Vaccine Injury Compensation Modernization Act of 2021
---H.R.3742: Vaccine Information for Nursing Facility Operators (INFO) Act
---H.R.3743: Supporting the Foundation for the National Institutes of Health and the Reagan-Udall Foundation for the Food and Drug Administration Act
---H.R.4127: A bill to amend title XVIII of the Social Security Act to encourage the development and use of DISARM antimicrobial drugs, and for other purposes.
---H.R. 8920/S.4760: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2021
---Adult Immunization
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---MCM Manufacturing & Capacity
---MCM R&D Incentives
---Vaccine Injury Compensation Program
---Vaccine and Antimicrobial Resistance Product Development and Incentives
Vaccine Injury Compensation Program
---FY 2022 Appropriations
---H.R.3655: Vaccine Injury Compensation Modernization Act of 2021
---H.R.3656: Vaccine Access Improvement Act of 2021
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Food & Drug Administration (FDA), White House Office, Natl Institutes of Health (NIH), Natl Security Council (NSC), Patent & Trademark Office (PTO), U.S. Trade Representative (USTR), Office of Science & Technology Policy (OSTP)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Hayley |
Alexander |
|
|
|
Jeanne |
Haggerty |
|
|
|
Aiken |
Hackett |
|
|
|
Shea |
Hartley |
|
|
|
Michael |
Mattoon |
|
|
|
Cartier |
Esham |
|
|
|
Camelia |
Thompson |
|
|
|
Hans |
Sauer |
|
|
|
John |
Murphy |
|
|
|
Joseph |
Damond |
|
|
|
Phyllis |
Arthur |
|
|
|
Joel |
Straus |
|
|
|
Kate |
Callanan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HOM
16. Specific lobbying issues
Biodefense Research, Development and Procurement Issues (Non-Funding)
---Executive Order on Modernizing Influenza Vaccines
---White House National Biodefense Strategy
Funding for Antimicrobial Resistance (AMR) Programs
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1319: American Rescue Plan Act of 2021
---H.R. 8920/S.4760: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2021
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1319: American Rescue Plan Act of 2021
---Funding for Strategic National Stockpile
---Health Defense Operations Funding Designation
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Natl Security Council (NSC), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jeanne |
Haggerty |
|
|
|
Michael |
Mattoon |
|
|
|
Phyllis |
Arthur |
|
|
|
Joel |
Straus |
|
|
|
Aiken |
Hackett |
|
|
|
Kate |
Callanan |
|
|
|
Hayley |
Alexander |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Biodefense Research, Development and Procurement Issues (Non-Funding)
---Executive Order on Modernizing Influenza Vaccines
---White House National Biodefense Strategy
Coronavirus (COVID-19) Pandemic
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1319: American Rescue Plan Act of 2021
---Immunization Information Systems
---R&D Funding for Medical Countermeasures
---Senate HELP Pandemic Preparedness White Paper
Funding for Antimicrobial Resistance (AMR) Programs
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1319: American Rescue Plan Act of 2021
---H.R. 8920/S.4760: Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act of 2021
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
Funding for Biodefense/Biomedical/Emergency Preparedness Research, Development and Procurement
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1319: American Rescue Plan Act of 2021
---Funding for Strategic National Stockpile
---Health Defense Operations Funding Designation
---Implementation of the Coronavirus Preparedness and Response Supplemental Appropriations Act for FY 2020
Funding for National Institutes of Health
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1319: American Rescue Plan Act of 2021
---H.R.3743: Supporting the Foundation for the National Institutes of Health and the Reagan-Udall Foundation for the Food and Drug Administration Act
---Advanced Research Projects Agency for Health (ARPA-H)
Funding for the Centers for Disease Control and Prevention Vaccine Programs
---FY 2022 Appropriations
---H.R.133: Consolidated Appropriations Act for FY 2021
---H.R.1319: American Rescue Plan Act of 2021
---Funding for 2020-2021 Influenza Season Preparedness and Response
---Funding for Routine Immunization Infrastructure during Pandemic
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Health & Human Services - Dept of (HHS), Office of Science & Technology Policy (OSTP)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jeanne |
Haggerty |
|
|
|
Michael |
Mattoon |
|
|
|
Phyllis |
Arthur |
|
|
|
Joel |
Straus |
|
|
|
Aiken |
Hackett |
|
|
|
Kate |
Callanan |
|
|
|
Hayley |
Alexander |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
21st Century Cures Act 2.0
---House Discussion Draft
---RFI from House Energy and Commerce Committee
340B Drug Discount Program
---H.R.3203: A bill to enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes.
---Program Implementation & Oversight
Coronavirus (COVID-19) Pandemic
---Implementation of the Coronavirus Aid, Relief, and Economic Security (CARES) Act of 2020
---Implementation of the Families First Coronavirus Response Act of 2020
---Patient Cost-Sharing and Smoothing
Drug Manufacturing, Quality & Distribution
---A bill to amend the Internal Revenue Code of 1986 to provide for credits against tax for domestic medical and drug manufacturing and advanced medical manufacturing equipment. (Discussion Draft)
Drug Pricing
---FY 2022 Appropriations
---H.R.3: Elijah E. Cummings Lower Drug Costs Now Act
---H.R.19/S.2164: Lower Costs, More Cures Act of 2021
---CMMI Authority
---COVID-19 Pricing-Related Provisions
---Drug Pricing Provisions
---Prescription Drug Pricing Reduction Act (Discussion Draft)
---Reference Pricing in Drug Reimbursement
---Senate Finance Committee Drug Pricing Principles
---Strengthening Innovation in Medicare and Medicaid Act (Discussion Draft)
Medicaid
---H.R.3: Elijah E. Cummings Lower Drug Costs Now Act
---H.R.2170/S.581: Helping Adults Protect Immunity (HAPI) Act of 2021
---H.R.2347: Strengthening the Vaccines for Children Program Act of 2021
---Pricing and Rebates
---Senate Finance Committee Drug Pricing Principles
---Value-Based Purchasing (VBP) Rule
Reimbursement and Coverage of Innovative Products
---H.R.3: Elijah E. Cummings Lower Drug Costs Now Act
---H.R.19/S.2164: Lower Costs, More Cures Act of 2021
---Administration Rebate Rule
---CMMI Authority
---Drug Pricing Provisions
---Medicare Part B Physician-Administered Products
---New Opportunities for Value that Extend Lives (NOVEL) Act (Discussion Draft)
---Patient Cost-Sharing and Smoothing
---Protected Classes
---Reference Pricing in Drug Reimbursement
---Senate Finance Committee Drug Pricing Principles
---Strengthening Innovation in Medicare and Medicaid Act (Discussion Draft)
---Step Therapy
---Value-Based Purchasing (VBP) Rule
---Value-based Contracting and Communications
Vaccines and Infectious Diseases
---H.R.1978: Protecting Seniors through Immunizations Act
---H.R.2170/S.581: Helping Adults Protect Immunity (HAPI) Act of 2021
---H.R.2347: Strengthening the Vaccines for Children Program Act of 2021
---H.R.4127: A bill to amend title XVIII of the Social Security Act to encourage the development and use of DISARM antimicrobial drugs, and for other purposes.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), White House Office
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jeanne |
Haggerty |
|
|
|
Michael |
Mattoon |
|
|
|
Aiken |
Hackett |
|
|
|
Joel |
Straus |
|
|
|
John |
Murphy |
|
|
|
Kate |
Callanan |
|
|
|
Phyllis |
Arthur |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code SMB
16. Specific lobbying issues
Capital Formation Incentives
---H.R.2140/S.961: American Innovation Act
---H.R.3448: Helping Startups Continue to Grow Act
---A bill to amend the Internal Revenue Code of 1986 to add a new medical research component to the credit for increasing research activities (Discussion Draft)
---A bill to amend the Internal Revenue Code of 1986 to make a portion of research credit refundable for certain small businesses engaging in specified medical research. (Discussion Draft)
---Incentives for Sustainable Aviation Fuels
---Proposed amendments under the Exchange Act of 1934
---Proposed amendments under the Investment Company Act of 1940
---Proposed amendments under the Securities Act of 1933
Capital Market Enhancements
---Accredited Investor Definition
---Amended Definition of Smaller Reporting Company
---Market Liquidity Proposals
---SEC Small Business Reform
Sarbanes Oxley Section 404 (b)
---Small Issuer Exemption
Short Selling Transparency
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jeanne |
Haggerty |
|
|
|
Cameron |
Arterton |
|
|
|
Michael |
Mattoon |
|
|
|
Shea |
Hartley |
|
|
|
Cartier |
Esham |
|
|
|
Aiken |
Hackett |
|
|
|
Kate |
Callanan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Capital Formation Incentives
---H.R.2140/S.961: American Innovation Act
---H.R.3448: Helping Startups Continue to Grow Act
---A bill to amend the Internal Revenue Code of 1986 to add a new medical research component to the credit for increasing research activities (Discussion Draft)
---A bill to amend the Internal Revenue Code of 1986 to make a portion of research credit refundable for certain small businesses engaging in specified medical research. (Discussion Draft)
---Incentives for Sustainable Aviation Fuels
---Proposed amendments under the Exchange Act of 1934
---Proposed amendments under the Investment Company Act of 1940
---Proposed amendments under the Securities Act of 1933
Vaccine Injury Compensation Program
---H.R.3656: Vaccine Access Improvement Act of 2021
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Jeanne |
Haggerty |
|
|
|
Cameron |
Arteron |
|
|
|
Michael |
Mattoon |
|
|
|
Cartier |
Esham |
|
|
|
Shea |
Hartley |
|
|
|
Aiken |
Hackett |
|
|
|
Kate |
Callanan |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Digital Trade
---EU Digital Strategy
Drug Pricing
--- Reference Pricing in Drug Reimbursement
Foreign Agricultural Biotechnology Laws and Regulations
---China Biotechnology Regulations
---EU Ag-Biotech Policies and Regulations
---Mexico Draft Decree Banning Genetically Modified Corn
---Mexico Import Approval Delays of Ag Biotech
Intellectual Property International Enforcement
---China
---TRIPS Waiver
The United States-Mexico-Canada Agreement (USMCA)
---Implementation of United States-Mexico-Canada Agreement (USMCA)
------Ag-Biotech Provisions
------IP Provisions
---Mexico Draft Decree Banning Genetically Modified Corn
---Mexico Import Approval Delays of Ag Biotech
US-China Trade Agreement
---Ag-Biotech Provisions
---IP Provisions
US-EU Trade Agreement
---Ag-Biotech Provisions
World Trade Organization
---TRIPS Waiver
---United States Withdrawal from the World Trade Organization (WTO)
World Health Organization (WHO)
---TRIPS Waiver
---United States Withdrawal from the World Health Organization (WHO)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR), Agriculture - Dept of (USDA), Patent & Trademark Office (PTO), White House Office, Environmental Protection Agency (EPA), Natl Security Council (NSC), State - Dept of (DOS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
David |
Lachmann |
|
|
|
Jeanne |
Haggerty |
|
|
|
Michael |
Mattoon |
|
|
|
Erick |
Lutt |
|
|
|
Matthew |
O'Mara |
|
|
|
Joseph |
Damond |
|
|
|
Hans |
Sauer |
|
|
|
Melissa |
Brand |
|
|
|
Aiken |
Hackett |
|
|
|
Hayley |
Alexander |
|
|
|
Kate |
Callanan |
|
|
|
Phyllis |
Arthur |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |